Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
986.88B
Market cap986.88B
Price-Earnings ratio
53.27
Price-Earnings ratio53.27
Dividend yield
0.56%
Dividend yield0.56%
Average volume
3.03M
Average volume3.03M
High today
$1,048.12
High today$1,048.12
Low today
$1,018.00
Low today$1,018.00
Open price
$1,024.43
Open price$1,024.43
Volume
1.49M
Volume1.49M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

As of today, Eli Lilly(LLY) shares are valued at $1,043.89. The company's market cap stands at 986.88B, with a P/E ratio of 53.27 and a dividend yield of 55.7%.

On 2026-01-16, Eli Lilly(LLY) stock moved within a range of $1,018.00 to $1,048.12. With shares now at $1,043.89, the stock is trading +2.5% above its intraday low and -0.4% below the session's peak.

Trading volume for Eli Lilly(LLY) stock has reached 1.49M, versus its average volume of 3.03M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

TipRanks 23m
Eli Lilly’s New Dulaglutide Study Targets Real-World Safety Questions for GLP-1 Investors

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Unlock hedge fund-level data and powerful invest...

TipRanks 24m
Eli Lilly Quietly Advances New Oral Candidate With Completion of Phase 1 Study in China

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: Eli Lilly and Company, togethe...

TipRanks 25m
Lilly Advances Next-Wave Obesity Pipeline With Japanese Phase 1 Combo Study

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Study Overview: Eli Lilly and Company is runni...

Analyst ratings

79%

of 29 ratings
Buy
79.3%
Hold
17.2%
Sell
3.4%

More LLY News

TipRanks 26m
Eli Lilly’s Olomorasib Capsule Study Signals Steady Pipeline Progress for Investors

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium Eli Lilly’s Olomorasib Capsule Study Offers Fr...

The Motley Fool 2h
Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know.

The high-powered duo is teaming up to build and equip a $1 billion research facility in California. In a corporate partnership many investors didn't see coming...

Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know.
Simply Wall St 18h
Is It Too Late To Consider Eli Lilly After The GLP 1 Weight Loss Boom?

If you are wondering whether Eli Lilly's share price still reflects fair value after a strong multi year run, you are not alone. The stock closed at US$1,032.9...

Is It Too Late To Consider Eli Lilly After The GLP 1 Weight Loss Boom?
Sherwood News 20h
Chipmakers power stock gains

Eli Lilly dipped after a report that FDA approval of its weight loss pill is delayed to Q2. The pharma company was also in the news as a lawsuit from Strive Spe...

Chipmakers power stock gains
Benzinga 22h
Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers

Eli Lilly And Co (NYSE:LLY) shares are trading lower on Thursday. The company, along with Novo Nordisk (NYSE:NVO) , are reportedly being sued in Texas by compou...

Eli Lilly Stock Slips After Antitrust Lawsuit Against GLP-1 Providers
Sherwood News 1d
Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs. Strive Specialties, one of t...

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s
TipRanks 1d
Eli Lilly Stock Falls 5% After FDA Delays Decision on Company’s Weight-Loss Pill

The stock of pharmaceutical giant Eli Lilly (LLY) is down 5% on news that the U.S. Food and Drug Administration (FDA) has delayed a decision on whether to appro...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .